Atherosclerosis, the underlying cause of heart attacks, strokes and peripheral vascular disease, is one of the major killers in the world. By 2020 WHO statistics indicate that it will be the most common cause of morbidity and mortality in both the industrialised world and the underdeveloped world. The disease develops slowly over many years in the innermost layer of large and medium-sized arteries (Fig. 1) (Scott, 1995; Ross, 1999; Naumova and Scott, 2000; Glass and Witztum, 2001; Libby, 2001). It does not usually become manifest before the fourth of fifth decade, but then often strikes with devas­ tating suddenness. Fifty per cent of individuals still die (25 per cent immedi­ ately) from their first heart attack; and morbidity from coronary heart disease and stroke is very significant. The disease has a profound impact on health­ care services and on industrial economies. The lesions of atherosclerosis Autopsy studies show that in humans atherosclerosis begins in the first and second decade of life. A similar disease can be produced in experimental animals, where diet and genetics can be manipulated to produce identical lesions. The earliest lesions are fatty streaks. These consist of an accumulation of lipid-engorged macrophages (foam cells) and T and B lymphocytes in the arterial intima. With time, the fatty streaks progress to intermediate lesions, composed of foam cells and smooth muscle cells.
Les mer
Atherosclerosis, the underlying cause of heart attacks, strokes and peripheral vascular disease, is one of the major killers in the world. A similar disease can be produced in experimental animals, where diet and genetics can be manipulated to produce identical lesions.
Les mer
The pathogenesis of atherosclerosis and new opportunities for treatment and prevention.- Stroke: imaging and differential diagnosis.- Stroke — acute interventions.- Rehabilitation approaches to stroke.- CADASIL and genetics of cerebral ischaemia.- Diagnosis and management of vascular cognitive impairment and dementia.- The genetics of migraine: implication for treatment approaches.- Does schizophrenia result from developmental or degenerative processes?.
Les mer
GPSR Compliance The European Union's (EU) General Product Safety Regulation (GPSR) is a set of rules that requires consumer products to be safe and our obligations to ensure this. If you have any concerns about our products you can contact us on ProductSafety@springernature.com. In case Publisher is established outside the EU, the EU authorized representative is: Springer Nature Customer Service Center GmbH Europaplatz 3 69115 Heidelberg, Germany ProductSafety@springernature.com
Les mer

Produktdetaljer

ISBN
9783211838662
Publisert
2002-11-07
Utgiver
Vendor
Springer Verlag GmbH
Høyde
280 mm
Bredde
216 mm
Aldersnivå
Research, P, 06
Språk
Product language
Engelsk
Format
Product format
Heftet